The Patent Finder

Panbela Therapeutics, Inc.

Also on record
Records under this name other than the patents Panbela Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Showing 1 to 6 of 6 · Back to Panbela Therapeutics, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,529,326Eflornithine and Sulindac, Fixed Dose Combination Formulation
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,925,613Eflornithine and Sulindac, Fixed Dose Combination Formulation
Formerly held
In force
 · High confidence
In forceHigh confidence
US 12,350,246Eflornithine and Sulindac, Fixed Dose Combination Formulation
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,973,790Eflornithine and Sulindac, Fixed Dose Combination Formulation
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,591,286Methods for Producing (6S,15S)-3,8,13,18-Tetraazaicosane-6,15-DIOL
Formerly held
In force
 · Low confidence
In forceLow confidence
US 10,945,981Methods for Treating Familial Adenomatous Polyposis
Formerly held
In force
 · High confidence
In forceHigh confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited